Immix Biopharma Inc
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immix Biopharma's stock, expecting significant growth towards a target price of $14.
Financial Health
Immix Biopharma is showing promising cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMMX
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory steps can materially move the stock; outcomes are binary and subject to delays, so watch timelines and data closely.
Volatile Small‑Cap Profile
Market cap under $150M often means higher volatility and sensitivity to news or financing; potential upside exists but so does downside risk.
Partnership Potential
Collaborations or licensing deals can provide funding and validation; however, such agreements aren’t guaranteed and may take time to materialise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
